<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Personalized, genotype-directed therapy for advanced non-small cell lung cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Personalized, genotype-directed therapy for advanced non-small cell lung cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Personalized, genotype-directed therapy for advanced non-small cell lung cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lecia V Sequist, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joel W Neal, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rogerio C Lilenbaum, MD, FACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 01, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H9880656"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Treatment for patients with metastatic non-small cell lung cancer (NSCLC) has historically consisted of systemic cytotoxic chemotherapy. Chemotherapy has a general goal of killing cells that are growing or dividing; chemotherapy reduces symptoms, improves quality of life, and prolongs survival in some patients with NSCLC.</p><p>An improved understanding of the molecular pathways that drive malignancy in NSCLC, as well as other neoplasms, led to the development of agents that target specific molecular pathways in malignant cells beginning in the early 2000s. The hope is that these agents will be able to preferentially kill malignant cells, but will be relatively innocuous to normal cells. Many established targeted therapies are administered as orally available, small-molecule kinase inhibitors, but targeted therapy can also be administered intravenously in the form of monoclonal antibodies or small molecules.</p><p>The identification of oncogenic activation of particular tyrosine kinases in some advanced NSCLC tumors, most notably mutations in the epidermal growth factor receptor (<em>EGFR</em>) or rearrangements of the anaplastic lymphoma kinase (<em>ALK</em>) gene or c-ROS oncogene 1 (<em>ROS1</em>) gene, has led to a paradigm shift and the development of specific molecular treatments for patients. Furthermore, the identification of these patient subsets has led to an ongoing effort to identify biomarkers and treatments that can be used for other subsets of patients with advanced NSCLC. Unfortunately, the proportion of patients with advanced adenocarcinoma receiving tumor genetic testing remains low, and it is therefore important to increase awareness regarding potentially targetable genetic alterations. A general discussion of these alterations, as well as other potential driver mutations, is found in this topic. A treatment approach to advanced NSCLC, as well as more detailed discussion regarding <em>EGFR</em>-mutated and <em>ALK</em>-positive lung cancers, is found elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4630.html" rel="external">"Systemic therapy for advanced non-small cell lung cancer with an activating mutation in the epidermal growth factor receptor"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4621.html" rel="external">"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer"</a>.)</p><p></p><p class="headingAnchor" id="H9880663"><span class="h1">DRIVER MUTATIONS AS BIOMARKERS</span><span class="headingEndMark"> — </span>The most useful biomarkers for predicting the efficacy of targeted therapy in advanced NSCLC are somatic genome alterations known as "driver mutations." These mutations occur in cancer cells within genes encoding for proteins critical to cell growth and survival. Many other recurrent molecular alterations have been identified in NSCLC that are much less essential to maintain the oncogenic phenotype and are often referred to as "passenger mutations." Driver mutations are typically not found in the germline (noncancer) genome of the host and are usually mutually exclusive (ie, a cancer is unlikely to have more than one driver mutation)  (<a class="graphic graphic_figure graphicRef86507" href="/z/d/graphic/86507.html" rel="external">figure 1</a>).</p><p>Driver mutations are typically transforming, which means that they initiate the evolution of a noncancerous cell to malignancy. In addition, driver mutations often impart an oncogene-addicted biology to the transformed cell, meaning that the mutated protein engenders reliance within the cancer cell to receive a signal from the driver in order to survive.</p><p>An often-used analogy is that a normally functioning cell may have a particular switch in its circuitry that is sometimes turned on and sometimes turned off, but in general is regulated with feedback inhibition loops and specific stimulators. However, in an oncogene-addicted cancer cell, the switch is stuck in the on position all the time and is no longer subject to regulation.</p><p>Oncogene addiction tends to make driver mutations good biomarkers for selecting patients for targeted therapies. The extreme reliance of crucial downstream growth and survival pathways in the cell upon a single upstream signal that is "stuck in the on position" serves as an Achilles' heel, making the cancer uniquely susceptible to downregulation of signal originating from the driver (ie, unable to survive if a targeted drug essentially turns the switch to the off position because other mechanisms to keep downstream signals flowing are nonexistent).</p><p>In NSCLC, as well as with other malignancies, matching a specific targeted drug to the identified driver mutation for an individual patient has resulted in significantly improved therapeutic efficacy, often in conjunction with decreased toxicity. Screening for driver mutations thus has become an increasingly standard part of the diagnostic work-up for NSCLC, and the resultant information is useful in choosing between standard chemotherapy in the absence of a targetable driver mutation versus upfront targeted therapies. As examples, in a nationwide French study in which all lung cancers were subjected to molecular profiling, approximately 50 percent of tumors exhibited a genetic alteration, which led to use of a targeted agent as first-line therapy in one-half of these cases [<a href="#rid1">1</a>]. The presence of a genetic alteration was associated with improved first-line progression-free survival (10 versus 7.1 months) and overall survival (16.5 versus 11.8 months).</p><p>Similarly, in the United States, the Lung Cancer Mutation Consortium analyzed tumors from 1007 patients for at least one gene, and from 733 patients for 10 genes (patients with full genotyping), identifying a targetable driver mutation in 64 percent of the cases examined by full genotyping [<a href="#rid2">2</a>]. Among 260 patients with an oncogenic driver who received a targeted agent, the median survival was 3.5 years; among 318 patients with a driver but without targeted therapy, median survival was 2.4 years; and among 360 patients without a driver, median survival was 2.1 years. These studies underscore the potential clinical benefit and prognostic utility provided by large-scale utilization of molecular profiling in lung cancer.</p><p class="headingAnchor" id="H9880670"><span class="h1">MOLECULAR TESTING</span><span class="headingEndMark"> — </span>Patients with advanced NSCLC should have tumor assessed for the presence of driver mutations [<a href="#rid3">3</a>]. Guidelines from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association of Molecular Pathologists recommend analysis of either the primary tumor or of a metastasis for epidermal growth factor receptor (<em>EGFR</em>) and anaplastic lymphoma kinase (<em>ALK</em>) for all patients whose tumor contains any component of adenocarcinoma histology, or who have light- or never-smoking history [<a href="#rid4">4,5</a>].</p><p class="headingAnchor" id="H4850292"><span class="h2">Techniques</span><span class="headingEndMark"> — </span>Methods for screening NSCLC patients for driver mutations and other abnormalities are continually evolving, and there is no single standard platform for testing. Features that make a platform clinically useful are fast turnaround time (two weeks or less), cost efficiency, ability to be performed on clinically available samples, and semi-automation, eliminating reliance upon a single operator. For newly diagnosed nonsquamous NSCLC patients, we initially recommend testing for <em>EGFR</em> (by a method that takes &lt;1 to 2 weeks, on either tissue or blood) and <em>ALK</em> (by immunohistochemistry [IHC] or fluorescence in-situ testing [FISH]). Next-generation sequencing on tissue or blood can be performed in lieu of these tests, in parallel with these tests, or reflexed if these tests are all negative. Molecular testing can be performed on selected patients with squamous or other types of NSCLC, for example those with a light- or never-smoking history. In addition, we recommend programmed cell death ligand 1 (PD-L1) IHC testing on all patients, regardless of histology.</p><p>Techniques used commonly in the clinical setting are described below, with recommended testing for specific alterations summarized in the table  (<a class="graphic graphic_table graphicRef111926" href="/z/d/graphic/111926.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>DNA sequencing</strong> – Clinical testing of mutations in lung cancer started historically with sequencing (or direct sequencing) of the gene, which examines the entire length of a single gene for the presence of a mutation. Usually, turnaround is &lt;1 week. However, the sensitivity is lower than other methods that have since been more widely adopted. This is because the tumor cellularity with the mutation must be high (ideally higher than 10 percent) in the tissue sample in order to be detected by direct sequencing, otherwise the test may be falsely negative.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>DNA allele-specific testing</strong> – Allele-specific testing analyzes the DNA for a predefined abnormality, and largely replaced direct sequencing. Some centers use this as the default test to evaluate <em>EGFR</em> and other abnormalities. The raw DNA is typically amplified using polymerase chain reactions (PCR) before the search for the mutated allele is undertaken, allowing for rare signals to be detected with greater sensitivity. This method represents a technological leap forward from direct sequencing in that it is a multiplexed test and tends to be faster (a few days) and cheaper than sequencing of each gene individually. However, only prespecified targets can be identified. Thus, allele-specific testing cannot be used to identify new abnormalities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>DNA and RNA next-generation sequencing (NGS)</strong> – NGS overcomes many of the shortcomings of direct sequencing and allele-specific testing, and is rapidly becoming adopted by more centers. This massively parallel approach, relying heavily on automation, data storage, and computational processing, allows quantitative analysis of infrequent alleles and simultaneous evaluation of multiple genes or even whole genomes. It retains sensitivity even in specimens with low tumor cellularity, which is an improvement over direct sequencing, and can identify new abnormalities, which would not be detected by allele-specific testing. The sensitivity is high enough to identify many molecular rearrangements in blood (circulating tumor DNA [ctDNA]) (see <a class="local">'Liquid biopsies'</a> below). Moreover, NGS can often detect intronic gene alterations that would historically be identified only by FISH. We routinely use DNA NGS in our clinical practice. RNA-based sequencing tests are becoming more routine and may be more sensitive to detect gene fusions and <em>MET</em> exon-14 alterations than DNA-based methods.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluorescence in-situ testing (FISH)</strong> – FISH is typically used to detect gene rearrangements such as translocations and other alternations such as amplifications or deletions, for example, <em>ALK</em> or c-ROS oncogene 1 (<em>ROS1</em>) rearrangements. Identifying rearrangements uses two hybridizing DNA probes of different colors that separate when two parts of a gene have broken apart. (See  <a class="medical medical_review" href="/z/d/html/2893.html" rel="external">"Tools for genetics and genomics: Cytogenetics and molecular genetics", section on 'Fluorescence in situ hybridization'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunohistochemistry (IHC)</strong> – The role of IHC is evolving [<a href="#rid4">4,5</a>]. IHC is considered a sensitive and specific alternative to FISH in evaluating for <em>ALK</em>-positive NSCLC and is very reliable and rapid (one day). However, IHC is still evolving for the detection of other targetable genomic alterations. In lung cancer IHC is the only definitive method to assess for PD-L1 protein staining, since PD-L1 protein expression does not appear to be related to known genomic alterations in the <em>PD-L1</em> gene. Tumor PD-L1 protein expression should be ordered, in addition to tumor genotyping, to determine first-line treatment options in NSCLC beyond chemotherapy. (See  <a class="medical medical_review" href="/z/d/html/90312.html" rel="external">"Initial management of advanced non-small cell lung cancer lacking a driver mutation", section on 'Factors in choosing initial therapy'</a>.)</p><p></p><p class="headingAnchor" id="H1978104749"><span class="h2">Liquid biopsies</span><span class="headingEndMark"> — </span>While molecular diagnostics have traditionally been performed on solid tumor tissue, blood-based tests or so-called "liquid" biopsies are gaining popularity as they provide the opportunity to genotype in a less invasive and less expensive manner, potentially in cases with insufficient tumor samples for tissue sequencing, and may offer a chance to monitor the molecular features of a cancer through the course of treatment, or predict relapse after adjuvant treatment [<a href="#rid6">6-9</a>]. Some data have also suggested that such assays may be done on pleural and pericardial fluid as well [<a href="#rid10">10,11</a>].</p><p>The principle behind liquid biopsies is that cell-free ctDNA and/or circulating tumor cells (CTCs) are often present in the blood of patients with lung cancer [<a href="#rid12">12</a>]. Platforms available for clinical use focus almost exclusively on isolating and detecting ctDNA, rather than CTCs. PCR-based platforms include allele-specific PCR, which preferentially amplifies a mutant DNA molecule over wildtype DNA, and emulsion PCR assays, which perform PCR reactions in thousands of droplets of a sample to quantify mutant and wildtype DNA (eg, droplet digital PCR and BEAMing) [<a href="#rid13">13</a>]. While such assays may have a theoretical turnaround time of as little as one day, they generally cover a limited number of common mutations, such as <em>EGFR</em>, <em>KRAS</em>, <em>BRAF</em>, and <em>ALK</em>. NGS-based plasma genotyping platforms are much broader in scope but take one to three weeks for results. In general, all of these methods are highly specific, although some platforms may detect allelic alterations that are present at such a low frequency that they may be clinically insignificant or represent low-level sequencing background noise or clonal mutations in hematopoietic stem cells [<a href="#rid12">12-14</a>].</p><p>The US Food and Drug Administration has approved ctDNA tests to identify <em>EGFR</em> mutation-positive patients [<a href="#rid15">15-17</a>], and one of the tests uses NGS to also identify genetic abnormalities in 55 genes [<a href="#rid16">16</a>]. It is likely that as more data emerge, the use of liquid biopsies to assess other molecular abnormalities will become more widespread. (See <a class="local">'EGFR mutations'</a> below.)</p><p>However, a limitation of ctDNA-based liquid biopsies is that the types of studies have a higher chance of being falsely negative compared with traditional biopsies, given the minuscule and variable amounts of DNA that tumors may shed into circulation. Liquid biopsies may yield results that predict clinical response to targeted agents, but the sensitivity ranges between 60 and 80 percent [<a href="#rid18">18,19</a>]. The limited sensitivity of liquid biopsies is thought to reflect the biology that some cancers do not shed DNA into the bloodstream rather than a feature of any given assay. Mutation detection in blood has been associated with more advanced disease characteristics, including worsened performance status and prognosis and the presence of more metastatic sites [<a href="#rid20">20</a>]. Furthermore, tests for PD-L1 expression cannot be conducted on liquid biopsies. (See  <a class="medical medical_review" href="/z/d/html/90312.html" rel="external">"Initial management of advanced non-small cell lung cancer lacking a driver mutation", section on 'Factors in choosing initial therapy'</a>.)</p><p>Finally, we do not use such assays to screen for or diagnose lung cancer. Although blood-based assays to diagnose a variety of cancers have been described [<a href="#rid21">21-23</a>], further investigation is needed prior to routine clinical use. Screening for lung cancer is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7566.html" rel="external">"Screening for lung cancer"</a>.)</p><p class="headingAnchor" id="H9880677"><span class="h1">NSCLC GENOTYPES</span><span class="headingEndMark"> — </span>This section reviews the most common targetable driver mutations, as well as some frequently identified passenger alterations that may or may not be targetable. Appropriate therapies are also discussed.</p><p>Whenever possible, patients should be enrolled in formal clinical studies. In addition to individual studies, the National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) study, LUNG-MAP cooperative group study, and other platform trials often include substudies for many of the genomic alterations mentioned below (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02465060&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzh35RvrgLNrXQnXVeh%2FjIkFrqV2QhdAFnNrXLi9%2BXTNg%3D%3D&amp;TOPIC_ID=16538" target="_blank">NCT02465060</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03851445&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPPDF0O9LWHvAMyx1uIU%2Ftl3vOMnC1APWRR%2FfHt8mPWYCA%3D%3D&amp;TOPIC_ID=16538" target="_blank">NCT03851445</a>).</p><p class="headingAnchor" id="H3902134"><span class="h2">EGFR mutations</span><span class="headingEndMark"> — </span>Mutations in the epidermal growth factor receptor (<em>EGFR</em>) tyrosine kinase are observed in approximately 15 percent of NSCLC adenocarcinomas in the United States and occur more frequently in nonsmokers [<a href="#rid24">24</a>]. In Asian populations, the incidence of <em>EGFR</em> mutations is substantially higher, up to 62 percent [<a href="#rid25">25</a>]. The use of EGFR tyrosine kinase inhibitors (TKIs) is based upon the detection of these mutations, which may be detected either in solid tissue biopsies or in liquid biopsies [<a href="#rid26">26</a>]. Any Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory <em>EGFR</em> mutation result is generally acceptable for clinical decision-making [<a href="#rid27">27</a>]. In advanced NSCLC, the presence of an <em>EGFR</em> mutation confers a more favorable prognosis and strongly predicts for sensitivity to EGFR TKIs, and therefore, targeted therapy should be used ahead of chemotherapy and immunotherapy in <em>EGFR</em>-positive NSCLC. For patients treated progressing on a first- or second-generation EGFR TKI, we offer repeat tumor or liquid biopsy to identify mechanisms of acquired resistance. However, the use of first-line <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> may largely prevent the development of T790M resistance [<a href="#rid28">28</a>]. For patients with <em>EGFR</em>-positive NSCLC who previously have been exposed to immunotherapy, there are important toxicity considerations discussed elsewhere, along with a detailed discussion of the general treatment of <em>EGFR</em>-mutant NSCLC. (See  <a class="medical medical_review" href="/z/d/html/4630.html" rel="external">"Systemic therapy for advanced non-small cell lung cancer with an activating mutation in the epidermal growth factor receptor"</a>.)</p><p class="headingAnchor" id="H3902141"><span class="h2">ALK rearrangements</span><span class="headingEndMark"> — </span>Rearrangements involving the anaplastic lymphoma kinase (<em>ALK</em>) tyrosine kinase are present in approximately 4 percent of NSCLC adenocarcinomas in the United States and occur more frequently in nonsmokers and younger patients. <em>ALK</em> translocations can be identified by fluorescence in-situ testing (FISH), immunohistochemistry (IHC), or most next-generation sequencing (NGS) panels.</p><p>In advanced-stage NSCLC, the presence of an <em>ALK</em> gene rearrangement (<em>ALK</em>-positive NSCLC) strongly predicts for sensitivity to ALK TKIs (eg, <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">crizotinib</a>, <a class="drug drug_general" data-topicid="95046" href="/z/d/drug information/95046.html" rel="external">ceritinib</a>, <a class="drug drug_general" data-topicid="105868" href="/z/d/drug information/105868.html" rel="external">alectinib</a>, <a class="drug drug_general" data-topicid="112993" href="/z/d/drug information/112993.html" rel="external">brigatinib</a>, <a class="drug drug_general" data-topicid="119539" href="/z/d/drug information/119539.html" rel="external">lorlatinib</a>), and treatment with these agents significantly prolongs progression-free survival (PFS). The diagnosis and treatment of <em>ALK-</em>positive NSCLC is presented separately. (See  <a class="medical medical_review" href="/z/d/html/4621.html" rel="external">"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer"</a>.)</p><p class="headingAnchor" id="H1124188488"><span class="h2">ROS1 rearrangements</span><span class="headingEndMark"> — </span>c-ROS oncogene 1 (<em>ROS1</em>) is a receptor tyrosine kinase that acts as a driver oncogene in 1 to 2 percent of NSCLCs via a genetic translocation between <em>ROS1</em> and other genes, the most common of which is <em>CD74</em> [<a href="#rid29">29-32</a>]. Histologic and clinical features that are associated with <em>ROS1</em>-positive NSCLC include adenocarcinoma histology, younger patients, and never-smokers. <em>ROS1</em> translocations are identified by a FISH break-apart assay, similar to that used for <em>ALK</em> translocations, or by some NGS panels.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial treatment options</strong> – The <em>ROS1</em> tyrosine kinase is highly sensitive to the ROS1/MET inhibitor <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">crizotinib</a> as well as the ROS1/tropomyosin receptor kinase (TRK) inhibitors <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">entrectinib</a> and <a class="drug drug_general" data-topicid="143455" href="/z/d/drug information/143455.html" rel="external">repotrectinib</a>; these agents are US Food and Drug Administration (FDA) approved for patients with the <em>ROS1</em> translocation, including those who have received chemotherapy and those who are treatment naïve, and we suggest the use of any of these agent in the first-line setting, whenever possible [<a href="#rid33">33-36</a>]. Though the efficacy in systemic disease appears comparable, we favor entrectinib or repotrectinib for patients with central nervous system (CNS) involvement, due to better intracranial penetration [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/z/d/html/114697.html" rel="external">"Brain metastases in non-small cell lung cancer", section on 'ROS1 translocations'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Entrectinib</strong> – In a pooled analysis of three phase I or II trials including 161 patients with <em>ROS1 </em>fusion-positive NSCLC, with or without CNS metastases, the ORR to <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">entrectinib</a> was 67 percent, the median PFS was 15.7 months, and the 12-month OS was 81 percent. Responses appeared durable, with a median duration of response of 15.7 months [<a href="#rid37">37</a>]. Sixty-three percent of patients had received ≥1 prior line of systemic therapy. These results are similar to earlier analyses of these trials, which led to FDA approval [<a href="#rid34">34,38</a>]. In a pooled safety analysis including 355 patients, the most common adverse effects included fatigue (48 percent), edema (40 percent), constipation (46 percent), dysgeusia (44 percent), dizziness (38 percent), nausea (34 percent), dysesthesia (34 percent), cognitive impairment (27 percent), vomiting (24 percent), and pyrexia (21 percent) [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Repotrectinib</strong> – In a phase I/II study, among 71 patients who were naïve to tyrosine kinase inhibitors (TKIs), the objective response rate was 79 percent, the median PFS was 36 months and the 18-month survival rate was 88 percent; among 56 patients with one prior TKI and no chemotherapy, the objective response rate was 35 percent, the median PFS was nine months, and the median OS was 25 months [<a href="#rid39">39</a>]. Among 426 patients included in a safety analysis (irrespective of tumor type), grade ≥3 adverse events occurred in 29 percent, with the most common being anemia (in 4 percent) and increased blood creatine kinase level (in 4 percent). In a separate pooled safety analysis including 351 patients, the most common adverse effects included dizziness (64 percent), dysgeusia (50 percent), peripheral neuropathy (47 percent), constipation (37 percent), dyspnea (30 percent), ataxia (29 percent), and cognitive disorders (23 percent) [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Crizotinib</strong> – Observational data support the use of <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">crizotinib</a> for <em>ROS1</em>-positive NSCLCs [<a href="#rid40">40</a>]. In an open-label, international study of crizotinib of 53 patients with <em>ROS1</em>-positive NSCLC, over 80 percent of whom had received one or more prior chemotherapy regimens, the objective response rate (ORR) was 72 percent (6 complete and 32 partial responses). The median duration of response was 25 months, and the median PFS and overall survival (OS) were 19.3 and 51 months, respectively [<a href="#rid41">41,42</a>]. A similar response rate was observed in a phase II trial of crizotinib in 127 East Asian patients with <em>ROS1</em>-positive NSCLC, with median PFS of 15.9 months [<a href="#rid43">43</a>]. These results compare favorably with indirect comparisons with chemotherapy or chemoimmunotherapy, in which the median OS has been reported to be on the order of nine months to two years, respectively, as discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4629.html" rel="external">"Subsequent line therapy in non-small cell lung cancer lacking a driver mutation"</a> and  <a class="medical medical_review" href="/z/d/html/90312.html" rel="external">"Initial management of advanced non-small cell lung cancer lacking a driver mutation"</a>.)</p><p></p><p class="bulletIndent2">The side-effect profile associated with treatment was consistent with that seen when <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">crizotinib</a> has been used in <em>ALK</em>-positive NSCLC, and it has resulted in improved quality of life relative to patients on chemotherapy in a randomized trial in that setting [<a href="#rid44">44</a>]. However, the intracranial penetration of crizotinib is limited, and CNS-only relapses are often seen [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/z/d/html/4621.html" rel="external">"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer"</a> and  <a class="medical medical_review" href="/z/d/html/114697.html" rel="external">"Brain metastases in non-small cell lung cancer", section on 'ROS1 translocations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>After progression on </strong><strong>crizotinib</strong> – If a patient has experienced progression on <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">crizotinib</a>, we suggest <a class="drug drug_general" data-topicid="119539" href="/z/d/drug information/119539.html" rel="external">lorlatinib</a> as next-line therapy. Lorlatinib, approved in <em>ALK</em>-positive NSCLC after progression on other ALK inhibitors, appears to also overcome acquired resistance to crizotinib in <em>ROS1</em>-positive NSCLC. In a phase I/II trial including 69 patients with <em>ROS1</em>-positive NSCLC, 48 of whom had received a prior ROS1 TKI treatment, treatment with lorlatinib led to responses in both crizotinib-naïve patients (ORR, 62 percent) as well as in those with prior crizotinib exposure (ORR of 35 percent among those who had received crizotinib as their only prior TKI) [<a href="#rid45">45</a>]. Intracranial activity has also been demonstrated. After progression on lorlatinib, we move to nontargeted approaches (ie, chemotherapy and consideration of immunotherapy, though responses to immunotherapy are very rare [<a href="#rid46">46</a>]). (See  <a class="medical medical_review" href="/z/d/html/114697.html" rel="external">"Brain metastases in non-small cell lung cancer"</a> and  <a class="medical medical_review" href="/z/d/html/4621.html" rel="external">"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer"</a> and  <a class="medical medical_review" href="/z/d/html/90312.html" rel="external">"Initial management of advanced non-small cell lung cancer lacking a driver mutation"</a>.)</p><p></p><p>Other TKIs are also being tested in <em>ROS1</em>-positive NSCLC. Case reports suggest that <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a> may be effective in <em>ROS1</em>-translocated cancers that have become resistant to <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">crizotinib</a> [<a href="#rid47">47-49</a>]. Additionally, <a class="drug drug_general" data-topicid="95046" href="/z/d/drug information/95046.html" rel="external">ceritinib</a> has activity, though it does not otherwise appear to overcome acquired resistance to crizotinib. In a phase II trial of 28 evaluable patients with advanced <em>ROS1</em>-rearranged NSCLC, the ORR with ceritinib was 62 percent, duration of response was 21 months, and disease control rate was 81 percent [<a href="#rid50">50</a>]. The median PFS was 9.3 months overall and 19.3 months for crizotinib-naïve patients. Median OS was 24 months. Five of eight patients with brain metastases experienced disease control. However, with the improved CNS penetration of <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">entrectinib</a>, the role for this off-label strategy is unclear. <a class="drug drug_general" data-topicid="105868" href="/z/d/drug information/105868.html" rel="external">Alectinib</a> and <a class="drug drug_general" data-topicid="112993" href="/z/d/drug information/112993.html" rel="external">brigatinib</a>, while effective in <em>ALK</em>-positive NSCLC, have little to no established ROS1 inhibitory activity. Additionally, the investigational agent DS-6051b has emerging results in early-phase clinical trials in <em>ROS1</em> NSCLC [<a href="#rid51">51,52</a>].</p><p class="headingAnchor" id="H1887064896"><span class="h2">MET abnormalities</span><span class="headingEndMark"> — </span>MET is a tyrosine kinase receptor for hepatocyte growth factor. MET abnormalities include <em>MET</em> exon-14-skipping mutations (in 3 percent of lung adenocarcinomas and up to 20 percent of the relatively rare sarcomatoid-histology NSCLC) and <em>MET</em> gene amplification (in 2 to 4 percent of treatment-naïve NSCLC, and 5 to 20 percent of <em>EGFR</em>-mutated tumors that have acquired resistance to EGFR inhibitors) [<a href="#rid53">53-66</a>]. Exon-14-skipping mutations are most commonly found by DNA or RNA NGS, while <em>MET</em> amplification may be detected by FISH or some NGS panels [<a href="#rid67">67,68</a>]. Our approach is as follows.</p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>MET</em></strong><strong> exon-14-skipping mutations</strong> – The MET exon-14-skipping mutation reduces degradation of the MET protein, causing it to behave as an oncogenic driver. The MET inhibitors <a class="drug drug_general" data-topicid="128126" href="/z/d/drug information/128126.html" rel="external">capmatinib</a> and <a class="drug drug_general" data-topicid="130698" href="/z/d/drug information/130698.html" rel="external">tepotinib</a> are approved by the FDA for adult patients with a <em>MET</em> exon-14-skipping mutation, and we suggest the use of either in the front-line setting for such patients, rather than immunotherapy and/or chemotherapy [<a href="#rid69">69</a>]. However, alternatively, it is also acceptable to use these agents in the subsequent-line setting, after progression on chemotherapy and/or immunotherapy [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1">In the GEOMETRY-mono-1 trial including 97 patients with advanced NSCLC associated with a <em>MET</em> exon-14-skipping mutation, among 28 patients with treatment-naïve disease, the overall response rate with <a class="drug drug_general" data-topicid="128126" href="/z/d/drug information/128126.html" rel="external">capmatinib</a> was 68 percent and median PFS was 12.4 months; among 69 previously treated patients, the overall response rate was 41 percent and median PFS was 5.4 months [<a href="#rid71">71</a>]. The most common treatment-related adverse events included peripheral edema (43 percent), nausea (34 percent), increased creatinine (18 percent), and vomiting (19 percent). A separate phase I trial, as well as a retrospective series also reported responses to capmatinib in patients with NSCLC and these mutations [<a href="#rid64">64,72</a>]. Capmatinib also showed activity among the subset with brain metastases, as discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/114697.html" rel="external">"Brain metastases in non-small cell lung cancer", section on 'MET exon-14-skipping mutations'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="130698" href="/z/d/drug information/130698.html" rel="external">Tepotinib</a> has also demonstrated activity in a single-arm phase II trial of 152 patients with NSCLC and a <em>MET</em> exon-14-skipping mutation, in which the overall response rate with tepotinib was 46 percent, with a median duration of response of 11 months [<a href="#rid73">73</a>]. Peripheral edema was the main toxic effect of grade 3 or higher, occurring in 7 percent.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">Crizotinib</a> is another potent MET inhibitor, in addition to inhibiting ALK and ROS1. It was historically used off label in the treatment of <em>MET</em> NSCLC, but we no longer recommend it following the FDA approval of <a class="drug drug_general" data-topicid="128126" href="/z/d/drug information/128126.html" rel="external">capmatinib</a> for this indication. In a series of 65 patients with <em>MET</em> exon-14-altered NSCLCs treated with crizotinib, the ORR was 32 percent, with a median PFS of 7.3 months and duration of response of 9.1 months [<a href="#rid74">74</a>]. Smaller studies have also suggested activity in NSCLC with <em>MET</em> exon-14-skipping mutations [<a href="#rid66">66,75</a>]. <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">Cabozantinib</a>, a multitargeted TKI that has activity against MET, was given to a patient and resulted in five months of stable disease [<a href="#rid64">64,66</a>].</p><p></p><p class="bulletIndent1">The MET inhibitors glesatinib and savolitinib are also being tested in clinical trials, as well as the <em>EGFR</em>/<em>MET</em> bispecific antibody <a class="drug drug_general" data-topicid="131693" href="/z/d/drug information/131693.html" rel="external">amivantamab</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>MET</em></strong><strong> amplification</strong> – For those with <strong>high-level</strong> <strong><em>MET</em></strong><strong> amplification</strong> (&gt;5-fold increase in gene copy number [GCN] or <em>MET/CEP7</em> ratio &gt;5) who have progressed on chemotherapy and/or immunotherapy, or those who have <em>MET</em> amplification as determined by a CLIA-approved DNA NGS test, we suggest treatment with a MET inhibitor (eg, <a class="drug drug_general" data-topicid="128126" href="/z/d/drug information/128126.html" rel="external">capmatinib</a> or <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">crizotinib</a>) as next-line therapy. However, these agents are not yet approved for this indication by the FDA, and the ideal methodology for determining level of amplification and appropriate cutoffs for treatment are still an active area of research.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Capmatinib</strong> – In a phase I trial of 55 patients with advanced <em>MET</em>-dysregulated NSCLC, roughly three-quarters of whom had received two or more prior systemic therapies, the overall response rate to <a class="drug drug_general" data-topicid="128126" href="/z/d/drug information/128126.html" rel="external">capmatinib</a> among 15 patients with <em>MET</em> GCN ≥6 was 47 percent, with a median PFS of 9.3 months [<a href="#rid72">72</a>]. The response rates were 25 percent for those with <em>MET</em> GCN between 4 and 6, and 6 percent for those with GCN &lt;4. When MET<em> </em>overexpression was analyzed using other methods, the response rate among patients with a tumor <em>MET/CEP7</em> ratio of ≥2 was 44 percent, versus 22 percent for those with ratio &lt;2; and 27 percent for those with <em>MET</em> IHC 3+, 14 percent for IHC 2+, and 0 percent for those with IHC 0 to 1+.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Crizotinib</strong> – In a single-arm study including 38 patients with <em>MET</em> amplification by <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.sciencedirect.com%2Ftopics%2Fmedicine-and-dentistry%2Ffluorescence-in-situ-hybridization&amp;token=BEsWY9x%2BzKrcubz9fRhcN0%2FCsqglRScu3gootXkhRpUEauHERFlL%2FYT34zHnfUejMs2zpJeYdIHjEa%2Bsmdpns%2BEcEeyxhpcDCzAffO%2BWe1Lqg6FuArHL3KtbklPt0Enq&amp;TOPIC_ID=16538" target="_blank">FISH</a> testing (<em>MET</em>-to-<em>CEP7</em> ratio ≥1.8), those with high <em>MET</em> amplification (≥4 <em>MET</em>-to-<em>CEP7</em> ratio) had an ORR of 38 percent with <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">crizotinib</a> and median PFS of 6.7 months [<a href="#rid76">76</a>]. Those with medium <em>MET</em> amplification (&gt;2.2 to &lt;4 <em>MET</em>-to-<em>CEP7</em> ratio) had a response rate of 14 percent and PFS of 1.9 months. Those with low <em>MET</em> amplification (1.8 to ≤2.2 <em>MET</em>-to-<em>CEP7</em> ratio) had a response rate of 33 percent and PFS of 1.8 months.</p><p></p><p class="bulletIndent1">Increased MET expression may predict response to MET-targeted drugs, but also appears to be associated with an overall worse prognosis [<a href="#rid77">77,78</a>]. There are several clinical trials available of MET inhibitors for <em>MET</em>-amplified NSCLC.</p><p></p><p class="headingAnchor" id="H2071999055"><span class="h2">RET rearrangements</span><span class="headingEndMark"> — </span>The rearranged during transfection gene (<em>RET</em>) encodes a cell surface tyrosine kinase receptor that is frequently altered in medullary thyroid cancer. Recurrent rearrangements between <em>RET</em> and various fusion partners (coiled-coil domain containing 6 [<em>CCDC6</em>], kinesin family member 5B [<em>KIF5B</em>], nuclear receptor coactivator 4 [<em>NCOA4</em>]) have been identified in 1 to 2 percent of adenocarcinomas, and occur more frequently in younger patients and in never-smokers [<a href="#rid79">79-82</a>]. Rearrangements can be detected with break-apart FISH or NGS.</p><p>We suggest use of the RET inhibitor <a class="drug drug_general" data-topicid="128157" href="/z/d/drug information/128157.html" rel="external">selpercatinib</a> in the front-line setting rather than immunotherapy and/or chemotherapy, but we consider <a class="drug drug_general" data-topicid="129470" href="/z/d/drug information/129470.html" rel="external">pralsetinib</a> to be an acceptable alternative (though with less supporting data than selpercatinib) [<a href="#rid83">83,84</a>]. However, it is also acceptable to use these agents in the subsequent-line setting. Selpercatinib is also approved for patients with locally advanced <em>RET</em>-positive NSCLC [<a href="#rid84">84</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized phase III trial, among 212 patients with advanced <em>RET</em> fusion–positive NSCLC, <a class="drug drug_general" data-topicid="128157" href="/z/d/drug information/128157.html" rel="external">selpercatinib</a> improved median PFS relative to control treatment, which consisted of platinum-based chemotherapy, with or without <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, per investigator's choice (25 versus 11 months; HR 0.46, 95% CI 0.31-0.70) [<a href="#rid85">85</a>]. Improvements were observed with selpercatinib when compared with chemotherapy, irrespective of whether pembrolizumab was administered. Objective response rates were 84 versus 65 percent, respectively. The time to progression affecting the central nervous system was also better with selpercatinib (HR 0.28). Overall, the incidence of grade ≥3 events was higher with selpercatinib than with control treatment (70 versus 57 percent). The most frequent grade ≥3 events with selpercatinib were hypertension (20 percent), alanine aminotransferase increase (22 percent), and aspartate aminotransferase increase (13 percent).</p><p></p><p class="bulletIndent1">These results are consistent with the previous multicohort, open-label, phase I/II LIBRETTO-001 study [<a href="#rid86">86</a>], in which the overall response rate among 69 treatment-naïve patients with <em>RET</em> fusion-positive NSCLC was 84 percent, with a median PFS of 22 months and median duration of response of 20 months [<a href="#rid87">87</a>]. Among 247 patients previously treated with platinum chemotherapy, the overall response rate was 61 percent, with a median PFS of 25 months, and with a median duration of response of 29 months. (See  <a class="medical medical_review" href="/z/d/html/114697.html" rel="external">"Brain metastases in non-small cell lung cancer", section on 'RET fusions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Separately, in a multicohort, open-label study of 114 patients with metastatic <em>RET</em> fusion-positive NSCLC, among 27 patients with treatment-naïve disease, the overall response rate with <a class="drug drug_general" data-topicid="129470" href="/z/d/drug information/129470.html" rel="external">pralsetinib</a> was 70 percent, with 58 percent of responses lasting at least six months and median duration of response of 9 months [<a href="#rid83">83,88,89</a>]. Among 87 patients previously treated with platinum chemotherapy, the overall response rate was 61 percent, the median duration of response had not been achieved, and approximately 80 percent of responses lasted at least six months. Serious adverse reactions occurred in 45 percent of patients. Grade 3 to 4 events occurring in at least 2 percent included hypertension (14 percent), pneumonia (8 percent), diarrhea (3 percent), and fatigue (2 percent). Fatal adverse events occurred in 5 percent of patients, and occurred due to pneumonia and sepsis. Pralsetinib also showed activity among patients with brain metastases. (See  <a class="medical medical_review" href="/z/d/html/114697.html" rel="external">"Brain metastases in non-small cell lung cancer", section on 'RET fusions'</a>.)</p><p></p><p><a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">Cabozantinib</a>, <a class="drug drug_general" data-topicid="16484" href="/z/d/drug information/16484.html" rel="external">vandetanib</a>, <a class="drug drug_general" data-topicid="105868" href="/z/d/drug information/105868.html" rel="external">alectinib</a>, and <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> are multitargeted RET inhibitors that may be useful in certain circumstances as alternatives to <a class="drug drug_general" data-topicid="128157" href="/z/d/drug information/128157.html" rel="external">selpercatinib</a> and <a class="drug drug_general" data-topicid="129470" href="/z/d/drug information/129470.html" rel="external">pralsetinib</a>. They are approved by the FDA for other indications but are significantly less potent than the RET inhibitors discussed above. For example, in a phase II trial of cabozantinib including 25 evaluable patients, all of whom had <em>RET</em>-positive tumors, treatment with cabozantinib 60 mg/day led to partial responses in seven (28 percent) and stable disease in nine (36 percent) patients [<a href="#rid90">90,91</a>]. With a median follow-up of 8.9 months, the median PFS was 5.5 months and the median OS was 9.9 months. Reports have also described responses to vandetanib, sunitinib, and alectinib in patients whose tumors were <em>RET</em> positive [<a href="#rid92">92-95</a>]. In a retrospective registry study of 165 patients with <em>RET</em>-positive NSCLC, the response rates to cabozantinib, vandetanib, and sunitinib were 37, 18, and 22 percent, respectively [<a href="#rid96">96</a>].</p><p class="headingAnchor" id="H163136609"><span class="h2">BRAF mutations</span><span class="headingEndMark"> — </span><em>BRAF</em> is a downstream signaling mediator of Kirsten rat sarcoma viral oncogene homolog (<em>KRAS</em>) that activates the mitogen-activated protein kinase (MAPK) pathway. Activating <em>BRAF</em> mutations have been observed in 1 to 3 percent of NSCLCs and are usually associated with a history of smoking [<a href="#rid97">97-101</a>]. They can occur either at the V600 position of exon 15, like in melanoma, or outside this domain, and are detected typically using polymerase chain reactions (PCR) sequencing or NGS methods.</p><p class="headingAnchor" id="H3716369133"><span class="h3">Clinical characteristics and prognosis, according to mutation</span><span class="headingEndMark"> — </span>Patients with V600 <em>BRAF</em> mutations appear to have a better prognosis than those with non-V600 <em>BRAF</em> mutations [<a href="#rid100">100</a>]. In general, <em>BRAF</em>-mutant NSCLC (both V600 and non-V600) appears to respond better to immunotherapy than most driver oncogene NSCLC [<a href="#rid46">46</a>].</p><p>While sensitivity to TKIs has traditionally led investigators to distinguish <em>BRAF</em> mutations as either V600 or non-V600, a classification scheme (class I to III) that further categorizes <em>BRAF</em> mutations according to their functional impact on the MAPK pathway has also been proposed [<a href="#rid102">102,103</a>]. In this setting, V600 mutations that produce a constitutively active RAF kinase are categorized as class I. Non-V600 mutations are classified as either class II or III depending on whether they produce active or dead forms of the RAF kinase, respectively.</p><p>The clinical characteristics and prognosis of <em>BRAF-</em>mutated adenocarcinoma of the lung are illustrated by a single-center series of 63 patients diagnosed between 2009 and 2013 [<a href="#rid100">100</a>]. The majority (57 percent) had a V600E mutation, and 92 percent were smokers, although those with V600 mutations were more likely to be light or never-smokers compared with those with non-V600 mutations (42 versus 11 percent). Among the 32 patients with early-stage disease, six (19 percent) developed synchronous or metachronous second primary lung cancers, all of which contained mutations in <em>KRAS</em>. For those with advanced NSCLC, the prognosis was significantly better in those with a V600 mutation compared with non-V600 mutations (three-year survival rate, 24 versus 0 percent). Six of the 10 patients with advanced disease and a V600E mutation had a partial response to treatment with a BRAF inhibitor, three had stable disease, and the median duration of response was over six months. In this experience, no patients were treated with BRAF/MEK combination therapy.</p><p>A separate study of 236 patients with <em>BRAF</em>-mutated NSCLC reported similar differences between patients with V600 versus non-V600 mutations. In this cohort, OS was significantly longer among patients with class I V600 mutations (40.1 months) compared with patients with class II (13.9 months) or class III (15.6 months) non-V600 mutations [<a href="#rid104">104</a>]. Compared with patients with non-V600 mutations, those with V600 mutations also had lower rates of CNS metastases, a factor that may contribute to differences in outcomes.</p><p class="headingAnchor" id="H1197267998"><span class="h3">BRAF V600E mutation</span><span class="headingEndMark"> — </span>For patients with NSCLC with <em>BRAF</em> V600E mutations, combinations of BRAF and MEK inhibitors are effective; two combinations, <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">trametinib</a> and <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">encorafenib</a> plus <a class="drug drug_general" data-topicid="118324" href="/z/d/drug information/118324.html" rel="external">binimetinib</a>, are approved by the FDA [<a href="#rid105">105,106</a>]. We suggest the use of either of these agents in the front-line setting for such patients, rather than immunotherapy and/or chemotherapy, given the response rates and PFS observed in small phase II studies.</p><p>As in melanoma, combination therapy may be more durable than single-agent treatment. (See  <a class="medical medical_review" href="/z/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Dabrafenib plus trametinib'</a>.)</p><p>Although BRAF inhibition with single oral small-molecule TKIs (eg, <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">vemurafenib</a>, <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a>) initially appeared to be an effective strategy in the treatment of progressive <em>BRAF</em> V600-mutant NSCLC [<a href="#rid107">107,108</a>], subsequent trials demonstrated that combination therapy consisting of BRAF and MEK inhibitors is the preferred treatment strategy:</p><p class="bulletIndent1"><span class="glyph">●</span>In a phase II study of 57 patients with previously treated, advanced NSCLC with the <em>BRAF</em> V600E mutation, the combination of <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">trametinib</a> was associated with an ORR of 68 percent in 52 evaluable patients, and the disease control rate was 81 percent [<a href="#rid109">109</a>]. The median PFS was 10.2 months. The side effect profile was consistent with that observed in dabrafenib plus trametinib clinical trials in patients with melanoma. (See  <a class="medical medical_review" href="/z/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'BRAF V600 mutant disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another cohort of the same phase II study, 36 previously untreated patients with advanced NSCLC and a <em>BRAF </em>V600E mutation were treated with <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">trametinib</a> [<a href="#rid109">109</a>]. The radiographic overall response rate was 64 percent and included two patients with a complete response and 21 with a partial response. The median PFS was 10.8 months as assessed by investigators.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The combination of <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">encorafenib</a> plus <a class="drug drug_general" data-topicid="118324" href="/z/d/drug information/118324.html" rel="external">binimetinib</a> has also demonstrated promising results in patients with <em>BRAF </em>V600E mutant metastatic NSCLC. In a single-arm study, among 98 patients with <em>BRAF </em>V600E mutant metastatic NSCLC (59 treatment-naïve and 39 previously treated, none with prior BRAF/MEK inhibitors), ORR was 75 percent in treatment-naïve and 46 percent in previously treated patients [<a href="#rid110">110</a>]. The median PFS was not estimable at a median follow up of 18 months in treatment-naïve patients; median PFS was 9.3 months in those with previous treatment. Treatment-related serious adverse events occurred in 14 percent, with the most common being colitis (3 percent).</p><p></p><p class="headingAnchor" id="H1925914224"><span class="h3">BRAF non-V600E mutations</span><span class="headingEndMark"> — </span>We do not generally recommend the use of BRAF or MEK inhibitors for non-V600E <em>BRAF</em>-mutant NSCLC.</p><p>Other strategies for patients whose cancers harbor <em>BRAF</em> mutations include the use of downstream MEK TKIs as monotherapy  (<a class="graphic graphic_figure graphicRef53134" href="/z/d/graphic/53134.html" rel="external">figure 2</a>). While this is of particular interest for some <em>BRAF</em> class II non-V600E tumors that generally appear insensitive to BRAF inhibitors, class III non-V600E <em>BRAF</em> mutations are kinase dead and would not be expected to respond to BRAF or MEK inhibition. (See  <a class="medical medical_review" href="/z/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"</a>.)</p><p class="headingAnchor" id="H3488267010"><span class="h2">NTRK fusions</span><span class="headingEndMark"> — </span>Fusions involving one of three tropomyosin receptor kinases (<em>TRK</em>) occur across many tumor types and are very rare (&lt;1 percent prevalent) in NSCLC. The oral TRK inhibitor <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">larotrectinib</a> is FDA approved for advanced tumors that have all of the following characteristics: harbor a neurotrophic receptor tyrosine kinase (<em>NTRK</em>) gene fusion, lack a known acquired resistance mutation, and have no satisfactory alternative treatments available (or have progressed following treatment) [<a href="#rid111">111</a>]. <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">Entrectinib</a> is another TRK inhibitor that is FDA approved in this setting [<a href="#rid112">112</a>]. Thus, for patients with advanced, <em>NTRK</em>-positive NSCLC, we suggest either larotrectinib or entrectinib, either in the first-line or subsequent treatment setting.</p><p>The efficacy of <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">larotrectinib</a> has been shown in early-phase clinical trials [<a href="#rid113">113-115</a>]. For example, in an analysis of three phase I/II trials including 159 patients with various <em>TRK</em> fusion-positive malignancies, the overall response rate by independent review was 79 percent [<a href="#rid115">115</a>]. Responses appeared durable, with 80 percent of responders still on treatment at a follow-up of 12 months. Of the 12 patients with lung tumors, nine experienced a response to treatment (response rate of 75 percent).</p><p>The FDA approval for <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">entrectinib</a> is based on combined results of several early-phase trials [<a href="#rid112">112,116,117</a>]. In a pooled analysis including 51 patients with <em>NTRK</em>-positive, unresectable or advanced tumors progressive NSCLC, the overall response rate was 63 percent, with a complete response rate of 11.8 percent [<a href="#rid117">117</a>]. Further details of entrectinib in TRK-positive cancers are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/122713.html" rel="external">"TRK fusion-positive cancers and TRK inhibitor therapy", section on 'Efficacy of first-generation TRK inhibitors'</a>.)</p><p><a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">Entrectinib</a> and <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">larotrectinib</a> have not been compared head-to-head. As shown above, response rates in small, nonrandomized trials are similar. In the absence of direct comparisons, either option is appropriate for those with <em>NTRK</em>-positive NSCLC.</p><p class="headingAnchor" id="H1827707998"><span class="h2">NRG1 fusions</span><span class="headingEndMark"> — </span>Fusions involving the neuregulin 1 (<em>NRG1</em>) gene are rare (&lt;1 percent prevalent) in NSCLC and are most reliably detected with tissue RNA NGS. Retrospective data have suggested poor activity of chemotherapy and immunotherapy in <em>NRG1</em>-fusion cancers. In an analysis of <em>NRG1</em> fusion-positive lung cancers from 22 centers, objective response rate and median PFS to platinum-doublet chemotherapy were 13 percent and 5.8 months, respectively; the activity of chemoimmunotherapy and single-agent immunotherapy was also poor (ORR 0 percent/PFS 3.3 months and ORR 20 percent/PFS 3.6 months, respectively) [<a href="#rid118">118</a>].</p><p>A case series of five patients who received <a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">afatinib</a> therapy for <em>NRG1</em>-positive lung cancer demonstrated four partial radiographic responses in five patients, with three of these lasting over 18 months [<a href="#rid119">119</a>]. Other targeted therapeutics against <em>NRG1</em> fusions are in clinical trial development, such as seribantumab.</p><p class="headingAnchor" id="H644244571"><span class="h2">RAS mutations</span><span class="headingEndMark"> — </span>The <em>RAS</em> family of oncogenes was originally identified through the study of rat sarcoma(ras)-inducing retrovirus, and includes Kirsten rat sarcoma viral oncogene homolog (<em>KRAS</em>), neuroblastoma rat sarcoma viral oncogene homolog (<em>NRAS</em>), and Harvey rat sarcoma viral oncogene homologs (<em>HRAS</em>) [<a href="#rid120">120</a>]. Activating <em>KRAS</em> mutations, which activate a number of downstream signaling pathways  (<a class="graphic graphic_figure graphicRef53134" href="/z/d/graphic/53134.html" rel="external">figure 2</a>), are observed in approximately 20 to 25 percent of lung adenocarcinomas in the United States, and are generally associated with smoking [<a href="#rid121">121,122</a>]. The presence of a <em>KRAS</em> mutation appears to have at most a limited effect on OS in patients with early-stage NSCLC [<a href="#rid123">123</a>], although some older data had suggested that it was associated with a worse prognosis [<a href="#rid124">124</a>]. <em>NRAS</em> is homologous to <em>KRAS</em>, associated with smoking, and mutations have been observed in approximately 1 percent of NSCLCs [<a href="#rid97">97</a>]. The clinical significance of <em>NRAS</em> mutations is unclear, and no effective targeted therapies have been identified.</p><p>The focus of targeted therapeutics for patients with <em>KRAS</em>-mutated lung cancer is against downstream effectors of activated <em>KRAS</em>  (<a class="graphic graphic_figure graphicRef53134" href="/z/d/graphic/53134.html" rel="external">figure 2</a>), based on previous supporting preclinical evidence [<a href="#rid125">125</a>], as well as irreversible inhibitors of KRAS G12C.</p><p>Multiple agents specifically targeting the <em>KRAS</em> G12C mutation, which comprises almost 50 percent of <em>KRAS</em> mutations in NSCLC, have emerged.</p><p class="headingAnchor" id="H2909254561"><span class="h3">Sotorasib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="131755" href="/z/d/drug information/131755.html" rel="external">Sotorasib</a> was the first targeted agent with regulatory approval for <em>KRAS</em> G12C-mutated NSCLC. It is approved by the FDA for patients with <em>KRAS </em>G12C-mutated locally advanced or metastatic NSCLC, who have received at least one prior systemic therapy [<a href="#rid126">126</a>]. Sotorasib has several drug interactions and should typically not be coadministered with proton pump inhibitors, H2-receptor antagonists, and strong cytochrome P450 3A4 (CYP3A4) inducers, and certain CYP3A4 substrates and P-gp substrates.</p><p>In an open-label, randomized controlled trial among 345 patients with <em>KRAS </em>G12C-mutated advanced NSCLC who experienced progression on platinum-based chemotherapy and a programmed cell death 1 or programmed cell death ligand 1 inhibitor, those assigned to <a class="drug drug_general" data-topicid="131755" href="/z/d/drug information/131755.html" rel="external">sotorasib</a> had a better PFS compared with the <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> group by blinded independent review (5.6 versus 4.5 months, HR 0.66, 95% CI 0.51-0.86), with fewer grade ≥3 toxicities (33 versus 40 percent) and serious treatment-related adverse events (11 versus 23 percent) [<a href="#rid127">127</a>]. OS was similar between the treatment groups (10.6 months with sotorasib and 11.3 months with docetaxel, HR 1.0). The most common treatment-related grade ≥3 adverse events were diarrhea (12 percent), and elevation in transaminases (5 to 8 percent).</p><p>In the previous phase I study, <a class="drug drug_general" data-topicid="131755" href="/z/d/drug information/131755.html" rel="external">sotorasib</a> was associated with an ORR of 41 percent, median PFS of 6.3 months, OS of 12.5 months, and two-year OS rate of 33 percent [<a href="#rid128">128</a>].</p><p class="headingAnchor" id="H1562822722"><span class="h3">Adagrasib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="140357" href="/z/d/drug information/140357.html" rel="external">Adagrasib</a> is a related molecule that also has FDA approval for patients with <em>KRAS </em>G12C-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy [<a href="#rid129">129</a>].</p><p>In a single arm study in 116 patients with <em>KRAS</em> G12C-mutated NSCLC, almost all of whom had received prior chemotherapy and immunotherapy, <a class="drug drug_general" data-topicid="140357" href="/z/d/drug information/140357.html" rel="external">adagrasib</a> 600 mg twice daily was associated with a median progression-free survival of 6.5 months, duration of response of 8.5 months, response rate of 43 percent, and overall survival of 12.6 months [<a href="#rid130">130</a>]. Among 33 patients with previously treated, stable central nervous system metastases, the intracranial confirmed objective response rate was 33 percent. Grade ≥3 treatment related adverse events occurred in 45 percent, the most common of which were fatigue, nausea, and increased liver function tests. There were two grade 5 events, one cardiac failure in a patient with a medical history of pericardial effusion and one pulmonary hemorrhage.</p><p class="headingAnchor" id="H3311741966"><span class="h3">Others</span><span class="headingEndMark"> — </span>Other agents are under investigation for G12C <em>KRAS</em>-mutant NSCLC. As an example, in a phase I study of 137 patients with advanced <em>KRAS</em>-mutant cancers, the objective response rate to the covalent KRAS G12C inhibitor divarasib (GDC-6036) was 53 percent among the 60 patients with NSCLC, with a median PFS of 13.1 months [<a href="#rid131">131</a>]. In the entire cohort, grade 3 events occurred in 15 patients (11 percent), and one patient experienced a grade 4 event (1 percent). Further data and/or regulatory approval are needed.</p><p>Based on available data, there are few promising treatments for non-G12C <em>KRAS</em>-mutant NSCLC. Results of a phase III trial with the oral MEK inhibitor <a class="drug drug_general" data-topicid="127843" href="/z/d/drug information/127843.html" rel="external">selumetinib</a> in combination with <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> did not demonstrate benefit of the MEK inhibitor strategy [<a href="#rid132">132</a>]. In this trial, 510 patients were randomized, but there were no differences observed in the selumetinib plus docetaxel arm compared with docetaxel alone with regard to PFS (3.9 versus 2.8 months), OS (8.7 versus 7.9 months), or response rate (20 versus 14 percent).</p><p>Mechanisms of resistance to <em>KRAS</em> inhibition have been described [<a href="#rid133">133</a>], and strategies to delay and overcome resistance are being investigated.</p><p class="headingAnchor" id="H1821155597"><span class="h2">HER2 mutations and amplifications</span><span class="headingEndMark"> — </span>Human epidermal growth factor receptor 2 (HER2 [<em>ERBB2</em>]) is an <em>EGFR</em> family receptor tyrosine kinase. Mutations in <em>HER2</em> have been detected using PCR or NGS in approximately 1 to 3 percent of NSCLC tumors [<a href="#rid134">134-136</a>]. They usually involve small in-frame insertions in exon 20, but point mutations in exon 20 have also been observed. These tumors are predominantly adenocarcinomas, are more prevalent among never-smokers, and a majority of these patients are women.</p><p>For patients with a <em>HER2</em> exon-20-insertion mutation, a trastuzumab-based antibody-drug conjugate (ADC) could be considered after progression on prior therapy. <a class="drug drug_general" data-topicid="126410" href="/z/d/drug information/126410.html" rel="external">Fam-trastuzumab deruxtecan</a> is approved by the FDA for patients with unresectable or metastatic NSCLC whose tumors have activating HER2-mutations, and who have received a prior systemic therapy [<a href="#rid137">137</a>]. <a class="drug drug_general" data-topicid="88427" href="/z/d/drug information/88427.html" rel="external">Ado-trastuzumab emtansine</a> is approved for other indications and is an appropriate alternative. Supporting data are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fam-trastuzumab deruxtecan</strong> – In the DESTINY-Lung01 study, <a class="drug drug_general" data-topicid="126410" href="/z/d/drug information/126410.html" rel="external">fam-trastuzumab deruxtecan</a> (T-DXd) was administered at 6.4 mg/kg to 91 patients with <em>HER2</em> mutation-positive NSCLC that had progressed on standard treatment, with a median PFS of 8.2 months, overall survival of 17.8 months, and response rate of 55 percent [<a href="#rid138">138</a>]. In a separate study in 152 patients with <em>HER2-</em>mutant NSCLC, T-DXd 5.4 and 6.4 mg/kg were associated with objective response rates of 49 and 56 percent, respectively, and grade ≥3 treatment-related adverse events of 39 and 58 percent, respectively [<a href="#rid139">139</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ado-</strong><strong>trastuzumab</strong><strong> emtansine</strong> – In a phase II trial of <a class="drug drug_general" data-topicid="88427" href="/z/d/drug information/88427.html" rel="external">ado-trastuzumab emtansine</a> in 18 patients with <em>HER2</em>-mutant advanced lung cancer, with a median of two prior lines of systemic therapy, the ORR was 44 percent, median PFS was five months, and the median duration of response was four months [<a href="#rid140">140</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trastuzumab</strong><strong>-based approaches and investigative options</strong> – Case and early-phase clinical trials suggest that patients with tumors harboring <em>HER2</em> mutations may also respond to trastuzumab-based regimens [<a href="#rid135">135,141-144</a>]. In a series of 65 patients receiving ERBB2-targeted therapies, the overall response rate was 51 percent. For those receiving <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">trastuzumab</a> in combination with chemotherapy and those receiving <a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">afatinib</a>, response rates were 50 and 18 percent, disease control rates were 75 and 64 percent, and PFS was 5.1 and 3.9 months, respectively [<a href="#rid145">145</a>].</p><p></p><p>Many other HER2-targeted small molecules are under study. For example, the small-molecule TKIs poziotinib, pyrotinib, and TAK-788 (<a class="drug drug_general" data-topicid="132715" href="/z/d/drug information/132715.html" rel="external">mobocertinib</a>) each have reported efficacy in <em>HER2</em> exon-20-insertion NSCLC [<a href="#rid146">146-151</a>].</p><p>There is no clear association between <em>HER2</em> amplification and <em>HER2</em> mutations. While early clinical trials demonstrated no benefit of targeted therapy in <em>HER2</em>-amplified NSCLC [<a href="#rid152">152,153</a>], a separate interim analysis of the DESTINY-Lung01 study discussed above showed a 24.5 percent response rate with <a class="drug drug_general" data-topicid="126410" href="/z/d/drug information/126410.html" rel="external">fam-trastuzumab deruxtecan</a> in HER2-overexpressed, IHC 2+ or 3+, <em>HER2</em> mutation-negative NSCLC, which may correlate with <em>HER2</em> amplification [<a href="#rid154">154</a>].</p><p class="headingAnchor" id="H1935929270"><span class="h2">Other genotypes</span><span class="headingEndMark"> — </span>Other alterations in oncogenes such as phosphatidylinositol 3-kinase (<em>PI3K</em>) and catenin beta-1 (<em>CTNNB1</em>), and tumor suppressors such as serine/threonine kinase 11 (<em>STK11</em> [<em>LKB1</em>]), kelch-like ECH-associated protein 1 (<em>KEAP1</em>), and nuclear factor erythroid 2-related factor 2 (<em>NFE2L2</em>) have not been demonstrated to be confer sensitivity to targeted therapy. However, <em>STK11</em> alterations may confer relative resistance to immunotherapy, and <em>KEAP1</em> mutations may increase resistance to radiotherapy. Therapeutics targeting these pathways are in clinical development.</p><p class="headingAnchor" id="H216174673"><span class="h1">SPECIAL CONSIDERATIONS</span></p><p class="headingAnchor" id="H1522970086"><span class="h2">Obese patients</span><span class="headingEndMark"> — </span>If targeted therapy is indicated, we suggest that standard drug doses be administered to all patients regardless of body mass index. This is consistent with clinical practice guidelines from the American Society of Clinical Oncology [<a href="#rid155">155</a>]. (See  <a class="medical medical_review" href="/z/d/html/83810.html" rel="external">"Dosing of anticancer agents in adults"</a>.)</p><p class="headingAnchor" id="H2788923591"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112231.html" rel="external">"Society guideline links: Diagnosis and management of lung cancer"</a>.)</p><p class="headingAnchor" id="H17849431"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Driver mutations as biomarkers</strong> – It is critical to identify biomarkers of the molecular pathways that drive malignancy in patients with non-small cell lung cancer (NSCLC), particularly in those patients with adenocarcinoma histology and a light- or never-smoking history regardless of histology, because of the availability of effective targeted agents for many of these cancers. Driver mutations often impart an oncogene-addicted biology to the transformed cell, meaning that the mutated protein confers cell growth and survival advantages for the cancer cell.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecular testing</strong> – The gold standard for molecular testing in NSCLC is tissue-based testing. At minimum, we recommend determination of epidermal growth factor receptor (<em>EGFR</em>) mutation status and anaplastic lymphoma kinase (<em>ALK</em>) rearrangement status prior to initiating therapy because rapid and sensitive tests are available, and initiation of immunotherapy could increase toxicity of tyrosine kinase inhibitors later in the patient's course. However, more comprehensive testing can also identify candidates for first-line treatment with US Food and Drug Administration-approved therapies for c-ROS oncogene 1 (<em>ROS1</em>), <em>BRAF</em>, <em>MET</em>, rearranged during transfection gene (<em>RET</em>), and neurotrophic receptor tyrosine kinase (<em>NTRK</em>). If <em>EGFR</em> and <em>ALK</em> are negative, more comprehensive testing (for example, next-generation sequencing) should be pursued, either prior to or concurrent with initiation of first line treatment. (See <a class="local">'Driver mutations as biomarkers'</a> above and <a class="local">'Molecular testing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Blood-based tests or so-called "liquid" biopsies, based on circulating tumor DNA, can provide a convenient and rapid method to comprehensively identify these biomarkers, though sensitivity is less than that in tissue, and programmed cell death ligand 1 testing cannot be performed with liquid biopsy. (See <a class="local">'Liquid biopsies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>EGFR </em></strong><strong>or </strong><strong><em>ALK</em></strong><em> </em>– For patients with advanced <em>EGFR-</em>mutant NSCLC, or ALK-positive NSCLC, initial treatment is with targeted therapy, as discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4630.html" rel="external">"Systemic therapy for advanced non-small cell lung cancer with an activating mutation in the epidermal growth factor receptor"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>ROS1</em></strong> – For patients with advanced ROS1-positive NSCLC, we suggest a ROS1 inhibitor (ie, <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">crizotinib</a>, <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">entrectinib</a>, or <a class="drug drug_general" data-topicid="143455" href="/z/d/drug information/143455.html" rel="external">repotrectinib</a>) in the first-line setting rather than chemotherapy or chemoimmunotherapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, if treatment was initiated prior to knowledge of the genetic alteration, it may be used upon progression on initial therapy. Although any of these agents may be chosen for those without brain metastases, entrectinib or repotrectinib is favored for those with central nervous system involvement. (See <a class="local">'ROS1 rearrangements'</a> above and  <a class="medical medical_review" href="/z/d/html/114697.html" rel="external">"Brain metastases in non-small cell lung cancer", section on 'ROS1 translocations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>MET</em></strong> – For patients with advanced NSCLC that harbors a <em>MET</em> exon-14-skipping mutation, we suggest <a class="drug drug_general" data-topicid="128126" href="/z/d/drug information/128126.html" rel="external">capmatinib</a> or <a class="drug drug_general" data-topicid="130698" href="/z/d/drug information/130698.html" rel="external">tepotinib</a> in the first-line setting (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), although it is also reasonable to use these agents in the subsequent line, after progression on chemotherapy and/or immunotherapy. For patients with <em>MET</em>-amplified advanced NSCLC a MET inhibitor is an appropriate later-line option, after progression on immunotherapy and chemotherapy options. (See <a class="local">'MET abnormalities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>RET</em></strong> – For patients with advanced NSCLC that is <em>RET</em> rearrangement-positive, we suggest <a class="drug drug_general" data-topicid="128157" href="/z/d/drug information/128157.html" rel="external">selpercatinib</a> in the first-line setting rather than chemotherapy or chemoimmunotherapy (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>), but consider <a class="drug drug_general" data-topicid="129470" href="/z/d/drug information/129470.html" rel="external">pralsetinib</a> to be a reasonable alternative. <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">Cabozantinib</a>, <a class="drug drug_general" data-topicid="16484" href="/z/d/drug information/16484.html" rel="external">vandetanib</a>, and <a class="drug drug_general" data-topicid="105868" href="/z/d/drug information/105868.html" rel="external">alectinib</a> are other RET inhibitors but appear less effective. (See <a class="local">'RET rearrangements'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>BRAF</em></strong> – For patients with advanced NSCLC whose tumors harbor a <em>BRAF</em> V600 mutation, we suggest either <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">trametinib</a> or <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">encorafenib</a> plus <a class="drug drug_general" data-topicid="118324" href="/z/d/drug information/118324.html" rel="external">binimetinib</a> in the first-line setting (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), although it is also reasonable to use it in the subsequent line after progression on chemotherapy and/or immunotherapy. For non-BRAF-V600E tumors, MEK inhibitors may be considered after standard treatment options have been exhausted. (See <a class="local">'BRAF mutations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>NTRK</em></strong> – For patients with advanced NSCLC that is neurotrophic receptor tyrosine kinase (<em>NTRK</em>)<em> </em>fusion-positive, either targeted therapy (ie, <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">larotrectinib</a> or <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">entrectinib</a>) or immunotherapy, with or without chemotherapy are appropriate front-line options, with a choice between these strategies driven by patient preference regarding toxicity profiles. (See <a class="local">'NTRK fusions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>KRAS</em></strong> – For patients with advanced NSCLC with a Kirsten rat sarcoma viral oncogene homolog (<em>KRAS</em>) G12C mutation that has progressed on a prior line of therapy, we suggest <a class="drug drug_general" data-topicid="131755" href="/z/d/drug information/131755.html" rel="external">sotorasib</a> or <a class="drug drug_general" data-topicid="140357" href="/z/d/drug information/140357.html" rel="external">adagrasib</a> rather than subsequent chemotherapy and/or immunotherapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For <em>KRAS</em> alterations other than G12C, there are no targeted therapy options, so only standard chemotherapy and/or immunotherapy is indicated. (See <a class="local">'Sotorasib'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>HER2</em></strong> – For patients with NSCLC with mutations in human epidermal growth factor receptor 2 (<em>HER2</em>), who have experienced progression on prior therapy, we suggest fam-trastuzumab-deruxtecan (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), although <a class="drug drug_general" data-topicid="88427" href="/z/d/drug information/88427.html" rel="external">ado-trastuzumab emtansine</a> or participation in clinical trials are also reasonable approaches. (See <a class="local">'HER2 mutations and amplifications'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Barlesi F, Mazieres J, Merlio JP, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 2016; 387:1415.</a></li><li><a class="nounderline abstract_t">Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014; 311:1998.</a></li><li><a class="nounderline abstract_t">Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013; 8:823.</a></li><li><a class="nounderline abstract_t">Lindeman NI, Cagle PT, Aisner DL, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Mol Diagn 2018; 20:129.</a></li><li><a class="nounderline abstract_t">Leighl NB, Rekhtman N, Biermann WA, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. J Clin Oncol 2014; 32:3673.</a></li><li><a class="nounderline abstract_t">Corcoran RB, Chabner BA. Application of Cell-free DNA Analysis to Cancer Treatment. N Engl J Med 2018; 379:1754.</a></li><li><a class="nounderline abstract_t">Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 2017; 545:446.</a></li><li><a class="nounderline abstract_t">Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the Evolution of Non-Small-Cell Lung Cancer. N Engl J Med 2017; 376:2109.</a></li><li><a class="nounderline abstract_t">Zugazagoitia J, Ramos I, Trigo JM, et al. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. Ann Oncol 2019; 30:290.</a></li><li><a class="nounderline abstract_t">Lee KWC, Li MSC, Gai W, et al. Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-Free DNA in Patients With Non-Small Cell Lung Cancer. JAMA Oncol 2023; 9:261.</a></li><li><a class="nounderline abstract_t">Mahmood K, Jampani P, Clarke JM, et al. High Yield of Pleural Cell-Free DNA for Diagnosis of Oncogenic Mutations in Lung Adenocarcinoma. Chest 2023; 164:252.</a></li><li><a class="nounderline abstract_t">Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov 2014; 4:650.</a></li><li><a class="nounderline abstract_t">Oxnard GR, Paweletz CP, Sholl LM. Genomic Analysis of Plasma Cell-Free DNA in Patients With Cancer. JAMA Oncol 2016.</a></li><li><a class="nounderline abstract_t">Hu Y, Ulrich BC, Supplee J, et al. False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. Clin Cancer Res 2018; 24:4437.</a></li><li class="breakAll">US Food and Drug Administration (FDA). FDA Premarket Approval: Cobas EGFR Mutation Test v2, Cobas DNA and cfDNA Sample Preparation Kit. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P120019s019 (Accessed on August 14, 2020).</li><li class="breakAll">US Food and Drug Administration (FDA). FDA Premarket Approval: Next-generation sequencing oncology panel, somatic or germline variant detection system. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p200010 (Accessed on August 14, 2020).</li><li class="breakAll">US Food and Drug Administration. FoundationOne CDx - P170019. https://www.fda.gov/medical-devices/recently-approved-devices/foundationone-cdx-p170019 (Accessed on October 07, 2020).</li><li><a class="nounderline abstract_t">Oxnard GR, Thress KS, Alden RS, et al. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2016; 34:3375.</a></li><li><a class="nounderline abstract_t">Sacher AG, Paweletz C, Dahlberg SE, et al. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. JAMA Oncol 2016; 2:1014.</a></li><li><a class="nounderline abstract_t">Wu YL, Sequist LV, Hu CP, et al. EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. Br J Cancer 2017; 116:175.</a></li><li><a class="nounderline abstract_t">Liu MC, Oxnard GR, Klein EA, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol 2020; 31:745.</a></li><li><a class="nounderline abstract_t">Taylor WC. Comment on 'Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA' by M. C. Liu et al. Ann Oncol 2020; 31:1266.</a></li><li><a class="nounderline abstract_t">Larson MH, Pan W, Kim HJ, et al. A comprehensive characterization of the cell-free transcriptome reveals tissue- and subtype-specific biomarkers for cancer detection. Nat Commun 2021; 12:2357.</a></li><li><a class="nounderline abstract_t">Kawaguchi T, Koh Y, Ando M, et al. Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study. J Clin Oncol 2016; 34:2247.</a></li><li><a class="nounderline abstract_t">Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 2014; 9:154.</a></li><li><a class="nounderline abstract_t">Merker JD, Oxnard GR, Compton C, et al. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol 2018; 36:1631.</a></li><li class="breakAll">List of cleared or approved companion diagnostic devices (in-vitro and imaging tools). US Food and Drug Administration. http://www.fda.gov/medicaldevices/productsandmedicalprocedures/invitrodiagnostics/ucm301431.htm (Accessed on September 13, 2019).</li><li><a class="nounderline abstract_t">Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378:113.</a></li><li><a class="nounderline abstract_t">Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012; 30:863.</a></li><li><a class="nounderline abstract_t">Rimkunas VM, Crosby KE, Li D, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res 2012; 18:4449.</a></li><li><a class="nounderline abstract_t">Chin LP, Soo RA, Soong R, Ou SH. Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. J Thorac Oncol 2012; 7:1625.</a></li><li class="breakAll">Lovly CM, Horn L, Pao W. ROS1 Fusions in Non-Small Cell Lung Cancer. My Cancer Genome. https://www.mycancergenome.org/content/disease/lung-cancer/ros1/67/ (Accessed on March 04, 2019).</li><li class="breakAll">Crizotinib capsules. United States Prescribing Information. US National Library of Medicine. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202570s017lbl.pdf (Accessed on September 13, 2019).</li><li class="breakAll">Entrectinib capsules. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf (Accessed on September 13, 2019).</li><li><a class="nounderline abstract_t">Hanna NH, Robinson AG, Temin S, et al. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. J Clin Oncol 2021; 39:1040.</a></li><li class="breakAll">AUGTYRO (repotrectinib) capsules, for oral use. US Prescribing Information. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218213s000lbl.pdf (Accessed on November 17, 2023).</li><li><a class="nounderline abstract_t">Dziadziuszko R, Krebs MG, De Braud F, et al. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. J Clin Oncol 2021; 39:1253.</a></li><li><a class="nounderline abstract_t">Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020; 21:261.</a></li><li><a class="nounderline abstract_t">Drilon A, Camidge DR, Lin JJ, et al. Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2024; 390:118.</a></li><li><a class="nounderline abstract_t">Patil T, Smith DE, Bunn PA, et al. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. J Thorac Oncol 2018; 13:1717.</a></li><li><a class="nounderline abstract_t">Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014; 371:1963.</a></li><li><a class="nounderline abstract_t">Shaw AT, Riely GJ, Bang YJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol 2019; 30:1121.</a></li><li><a class="nounderline abstract_t">Wu YL, Yang JC, Kim DW, et al. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2018; 36:1405.</a></li><li><a class="nounderline abstract_t">Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371:2167.</a></li><li><a class="nounderline abstract_t">Shaw AT, Solomon BJ, Chiari R, et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol 2019; 20:1691.</a></li><li><a class="nounderline abstract_t">Mazieres J, Drilon AE, Mhanna L, et al. Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget). J Clin Oncol 2018; 36S: ASCO #9010.</a></li><li><a class="nounderline abstract_t">Drilon A, Somwar R, Wagner JP, et al. A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer. Clin Cancer Res 2016; 22:2351.</a></li><li><a class="nounderline abstract_t">Katayama R, Kobayashi Y, Friboulet L, et al. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer. Clin Cancer Res 2015; 21:166.</a></li><li><a class="nounderline abstract_t">Chong CR, Bahcall M, Capelletti M, et al. Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer. Clin Cancer Res 2017; 23:204.</a></li><li><a class="nounderline abstract_t">Lim SM, Kim HR, Lee JS, et al. Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. J Clin Oncol 2017; 35:2613.</a></li><li><a class="nounderline abstract_t">Lin J, Kim D, Drillon A, et al. Safety and preliminary clinical activity of ropotrectinib (TPX-0005), a ROS1/TRK/LK inhibitor, in advanced ROS1 fusion-positive NSCLC. J Thorac Oncol 2018; 13S: WCLC #OA2.02.</a></li><li><a class="nounderline abstract_t">Katayama R, Gong B, Togashi N, et al. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Nat Commun 2019; 10:3604.</a></li><li><a class="nounderline abstract_t">Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3:75ra26.</a></li><li><a class="nounderline abstract_t">Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007; 104:20932.</a></li><li><a class="nounderline abstract_t">Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009; 27:1667.</a></li><li><a class="nounderline abstract_t">Kubo T, Yamamoto H, Lockwood WW, et al. MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer 2009; 124:1778.</a></li><li><a class="nounderline abstract_t">Chen HJ, Mok TS, Chen ZH, et al. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. Pathol Oncol Res 2009; 15:651.</a></li><li><a class="nounderline abstract_t">Okuda K, Sasaki H, Yukiue H, et al. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci 2008; 99:2280.</a></li><li><a class="nounderline abstract_t">Onozato R, Kosaka T, Kuwano H, et al. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol 2009; 4:5.</a></li><li><a class="nounderline abstract_t">Arcila ME, Oxnard GR, Nafa K, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011; 17:1169.</a></li><li><a class="nounderline abstract_t">Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039.</a></li><li><a class="nounderline abstract_t">Turke AB, Zejnullahu K, Wu YL, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010; 17:77.</a></li><li><a class="nounderline abstract_t">Awad MM, Oxnard GR, Jackman DM, et al. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. J Clin Oncol 2016; 34:721.</a></li><li><a class="nounderline abstract_t">Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 2015; 5:850.</a></li><li><a class="nounderline abstract_t">Liu X, Jia Y, Stoopler MB, et al. Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations. J Clin Oncol 2016; 34:794.</a></li><li><a class="nounderline abstract_t">Paik PK, Drilon A, Fan PD, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov 2015; 5:842.</a></li><li><a class="nounderline abstract_t">Camidge DR, Ou SHI, Shapiro G, et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). J Clin Oncol 2014; 32S: ASCO #8001.</a></li><li><a class="nounderline abstract_t">Spigel DR, Ervin TJ, Ramlau RA, et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2013; 31:4105.</a></li><li class="breakAll">Tepotinib tablets. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214096s000lbl.pdf (Accessed on February 09, 2021).</li><li class="breakAll">Capmatinib tablets. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf (Accessed on May 07, 2020).</li><li><a class="nounderline abstract_t">Wolf J, Seto T, Han JY, et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med 2020; 383:944.</a></li><li><a class="nounderline abstract_t">Schuler M, Berardi R, Lim WT, et al. Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial. Ann Oncol 2020; 31:789.</a></li><li><a class="nounderline abstract_t">Paik PK, Felip E, Veillon R, et al. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med 2020; 383:931.</a></li><li><a class="nounderline abstract_t">Drilon A, Clark JW, Weiss J, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med 2020; 26:47.</a></li><li><a class="nounderline abstract_t">Drilon AE, Camidge R, Ou S-H I, et al. Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC). J Clin Oncol 2016; 34S: ASCO #108.</a></li><li><a class="nounderline abstract_t">Camidge DR, Otterson GA, Clark JW, et al. Crizotinib in Patients With MET-Amplified NSCLC. J Thorac Oncol 2021; 16:1017.</a></li><li><a class="nounderline abstract_t">Ichimura E, Maeshima A, Nakajima T, Nakamura T. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 1996; 87:1063.</a></li><li><a class="nounderline abstract_t">Nakamura Y, Niki T, Goto A, et al. c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. Cancer Sci 2007; 98:1006.</a></li><li><a class="nounderline abstract_t">Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012; 18:378.</a></li><li><a class="nounderline abstract_t">Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012; 18:375.</a></li><li><a class="nounderline abstract_t">Wang R, Hu H, Pan Y, et al. RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non-Small-Cell Lung Cancer. J Clin Oncol 2012; 30:4352.</a></li><li><a class="nounderline abstract_t">Mukhopadhyay S, Pennell NA, Ali SM, et al. RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinib. J Thorac Oncol 2014; 9:1714.</a></li><li class="breakAll">Pralsetinib capsules. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213721s000lbl.pdf (Accessed on September 11, 2020).</li><li class="breakAll">RETEVMO® (selpercatinib) capsules, for oral use. US Food and Drug Administration. Available at: https://pi.lilly.com/us/retevmo-uspi.pdf?s=pi (Accessed on September 26, 2022).</li><li><a class="nounderline abstract_t">Zhou C, Solomon B, Loong HH, et al. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. N Engl J Med 2023; 389:1839.</a></li><li><a class="nounderline abstract_t">Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2020; 383:813.</a></li><li><a class="nounderline abstract_t">Drilon A, Subbiah V, Gautschi O, et al. Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. J Clin Oncol 2023; 41:385.</a></li><li><a class="nounderline abstract_t">Gainor JF, Curigliano G, Kim DW, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol 2021; 22:959.</a></li><li><a class="nounderline abstract_t">Griesinger F, Curigliano G, Thomas M, et al. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Ann Oncol 2022; 33:1168.</a></li><li><a class="nounderline abstract_t">Drilon A, Rekhtman N, Arcila M, et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol 2016; 17:1653.</a></li><li><a class="nounderline abstract_t">Drilon AE, Sima CS, Somwar R, et al. Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers. J Clin Oncol 2015; 33S: ASCO #8007.</a></li><li><a class="nounderline abstract_t">Gautschi O, Zander T, Keller FA, et al. A patient with lung adenocarcinoma and RET fusion treated with vandetanib. J Thorac Oncol 2013; 8:e43.</a></li><li><a class="nounderline abstract_t">Drilon A, Wang L, Hasanovic A, et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 2013; 3:630.</a></li><li><a class="nounderline abstract_t">Falchook GS, Ordóñez NG, Bastida CC, et al. Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol 2016; 34:e141.</a></li><li><a class="nounderline abstract_t">Detterbeck FC, Franklin WA, Nicholson AG, et al. The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016; 11:651.</a></li><li><a class="nounderline abstract_t">Gautschi O, Milia J, Filleron T, et al. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol 2017; 35:1403.</a></li><li><a class="nounderline abstract_t">Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011; 22:2616.</a></li><li><a class="nounderline abstract_t">Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011; 29:2046.</a></li><li><a class="nounderline abstract_t">Kinno T, Tsuta K, Shiraishi K, et al. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations. Ann Oncol 2014; 25:138.</a></li><li><a class="nounderline abstract_t">Litvak AM, Paik PK, Woo KM, et al. Clinical characteristics and course of 63 patients with BRAF mutant lung cancers. J Thorac Oncol 2014; 9:1669.</a></li><li><a class="nounderline abstract_t">Villaruz LC, Socinski MA, Abberbock S, et al. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Cancer 2015; 121:448.</a></li><li><a class="nounderline abstract_t">Yao Z, Torres NM, Tao A, et al. BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Cancer Cell 2015; 28:370.</a></li><li><a class="nounderline abstract_t">Yao Z, Yaeger R, Rodrik-Outmezguine VS, et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature 2017; 548:234.</a></li><li><a class="nounderline abstract_t">Dagogo-Jack I, Martinez P, Yeap BY, et al. Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer. Clin Cancer Res 2019; 25:158.</a></li><li class="breakAll">TAFINLAR (dabrafenib) capsules, for oral use, prescribing information. US Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202806s022lbl.pdf (Accessed on June 24, 2022).</li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf (Accessed on October 13, 2023).</li><li><a class="nounderline abstract_t">Planchard D, Kim TM, Mazieres J, et al. Dabrafenib in patients with BRAF V600-mutant advanced non-small cell lung cancer (NSCLC): A multicenter, open-label, phase II trial (BRF113928). Ann Oncol 2014; 25S: ESMO #LBA38_PR.</a></li><li><a class="nounderline abstract_t">Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med 2015; 373:726.</a></li><li><a class="nounderline abstract_t">Planchard D, Besse B, Groen HJM, et al. Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. J Thorac Oncol 2022; 17:103.</a></li><li><a class="nounderline abstract_t">Riely GJ, Smit EF, Ahn MJ, et al. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol 2023; 41:3700.</a></li><li class="breakAll">Larotrectinib oral solution. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf (Accessed on September 13, 2019).</li><li class="breakAll">Entrectinib. US FDA-approved drug products. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=212725 (Accessed on September 13, 2019).</li><li><a class="nounderline abstract_t">Hong DS, Bauer TM, Lee JJ, et al. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol 2019; 30:325.</a></li><li><a class="nounderline abstract_t">Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 2018; 378:731.</a></li><li><a class="nounderline abstract_t">Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 2020; 21:531.</a></li><li><a class="nounderline abstract_t">Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020; 21:271.</a></li><li><a class="nounderline abstract_t">Cho BC, Chiu CH, Massarelli E, et al. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer. Lung Cancer 2023; 188:107442.</a></li><li><a class="nounderline abstract_t">Drilon A, Duruisseaux M, Han JY, et al. Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. J Clin Oncol 2021; 39:2791.</a></li><li><a class="nounderline abstract_t">Cadranel J, Liu SV, Duruisseaux M, et al. Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series. Oncologist 2021; 26:7.</a></li><li><a class="nounderline abstract_t">Kirsten WH, Mayer LA. Morphologic responses to a murine erythroblastosis virus. J Natl Cancer Inst 1967; 39:311.</a></li><li><a class="nounderline abstract_t">Bacus S. KRAS mutation and amplification status predicts sensitivity to antifolate therapies in non-small cell lung cancer. Mol Cancer Ther 2011; 10.</a></li><li><a class="nounderline abstract_t">O'Byrne KJ, Gatzemeier U, Bondarenko I, et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 2011; 12:795.</a></li><li><a class="nounderline abstract_t">Shepherd FA, Domerg C, Hainaut P, et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol 2013; 31:2173.</a></li><li><a class="nounderline abstract_t">Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005; 92:131.</a></li><li><a class="nounderline abstract_t">Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14:1351.</a></li><li class="breakAll">Sotorasib tablets. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214665s003lbl.pdf (Accessed on January 24, 2023).</li><li><a class="nounderline abstract_t">de Langen AJ, Johnson ML, Mazieres J, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet 2023; 401:733.</a></li><li><a class="nounderline abstract_t">Dy GK, Govindan R, Velcheti V, et al. Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100. J Clin Oncol 2023; 41:3311.</a></li><li class="breakAll">KRAZATI (adagrasib) tablets, for oral use. US Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340s001lbl.pdf (Accessed on December 13, 2022).</li><li><a class="nounderline abstract_t">Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. N Engl J Med 2022; 387:120.</a></li><li><a class="nounderline abstract_t">Sacher A, LoRusso P, Patel MR, et al. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. N Engl J Med 2023; 389:710.</a></li><li><a class="nounderline abstract_t">Jänne PA, van den Heuvel MM, Barlesi F, et al. Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial. JAMA 2017; 317:1844.</a></li><li><a class="nounderline abstract_t">Awad MM, Liu S, Rybkin II, et al. Acquired Resistance to KRASG12C Inhibition in Cancer. N Engl J Med 2021; 384:2382.</a></li><li><a class="nounderline abstract_t">Arcila ME, Chaft JE, Nafa K, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 2012; 18:4910.</a></li><li><a class="nounderline abstract_t">Mazières J, Peters S, Lepage B, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013; 31:1997.</a></li><li><a class="nounderline abstract_t">Pillai RN, Behera M, Berry LD, et al. HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. Cancer 2017; 123:4099.</a></li><li class="breakAll">Highlights of prescribing information: Enhertu. Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761139s021lbl.pdf (Accessed on August 19, 2022).</li><li><a class="nounderline abstract_t">Li BT, Smit EF, Goto Y, et al. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med 2022; 386:241.</a></li><li><a class="nounderline abstract_t">Goto K, Goto Y, Kubo T, et al. Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial. J Clin Oncol 2023; 41:4852.</a></li><li><a class="nounderline abstract_t">Li BT, Shen R, Buonocore D, et al. Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. J Clin Oncol 2018; 36:2532.</a></li><li><a class="nounderline abstract_t">Li BT, Shen R, Buonocore D, Olah ZT. Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers: Results from a phase II basket trial. J Clin Oncol 2017; 35S: ASCO #8510.</a></li><li><a class="nounderline abstract_t">Cappuzzo F, Bemis L, Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 2006; 354:2619.</a></li><li><a class="nounderline abstract_t">De Grève J, Teugels E, Geers C, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer 2012; 76:123.</a></li><li><a class="nounderline abstract_t">Mazieres J, Lafitte C, Ricordel C, et al. Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial. J Clin Oncol 2022; 40:719.</a></li><li><a class="nounderline abstract_t">Mazières J, Barlesi F, Filleron T, et al. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Ann Oncol 2016; 27:281.</a></li><li><a class="nounderline abstract_t">Robichaux J, Heymach J, Negrao M, et al. A phase II trial of poziotinib in EFR and HER2 exon 20 mutant non-small cell lung cancer (NSCLC). J Thorac Oncol 2018; 13S: WCLC #OA02.06.</a></li><li><a class="nounderline abstract_t">Doebele R, Riely G, Neal J, et al. Safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 in NSCLC. J Thorac Oncol 2018; 13S: WCLC #P1.13-44</a></li><li><a class="nounderline abstract_t">Wang Y, Jiang T, Qin Z, et al. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib. Ann Oncol 2019; 30:447.</a></li><li><a class="nounderline abstract_t">Zhou C, Li X, Wang Q, et al. Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study. J Clin Oncol 2020; 38:2753.</a></li><li><a class="nounderline abstract_t">Le X, Cornelissen R, Garassino M, et al. Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. J Clin Oncol 2022; 40:710.</a></li><li><a class="nounderline abstract_t">Elamin YY, Robichaux JP, Carter BW, et al. Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. J Clin Oncol 2022; 40:702.</a></li><li><a class="nounderline abstract_t">Gatzemeier U, Groth G, Butts C, et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 2004; 15:19.</a></li><li><a class="nounderline abstract_t">Zinner RG, Glisson BS, Fossella FV, et al. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer 2004; 44:99.</a></li><li><a class="nounderline abstract_t">Nakagawa K, Nagasaka M, Felip E, et al. Trastuzumab deruxtecan in HER2-overexpressing metastatic non-small cell lung cancer: Interim results of DESTINY-Lung01. J Thorac Oncol 2021; 16S:S109; WCLC #OA04.05.</a></li><li><a class="nounderline abstract_t">Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2021; 39:2037.</a></li></ol></div><div id="topicVersionRevision">Topic 16538 Version 126.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26777916" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24846037" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23552377" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29398453" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25311215" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30380390" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Application of Cell-free DNA Analysis to Cancer Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28445469" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28445112" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Tracking the Evolution of Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30535340" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36580285" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-Free DNA in Patients With Non-Small Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36693563" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : High Yield of Pleural Cell-Free DNA for Diagnosis of Oncogenic Mutations in Lung Adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24801577" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27541382" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Genomic Analysis of Plasma Cell-Free DNA in Patients With Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29567812" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : False-Positive Plasma Genotyping Due to Clonal Hematopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29567812" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : False-Positive Plasma Genotyping Due to Clonal Hematopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29567812" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : False-Positive Plasma Genotyping Due to Clonal Hematopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29567812" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : False-Positive Plasma Genotyping Due to Clonal Hematopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27354477" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27055085" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28006816" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33506766" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32371122" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Comment on 'Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA' by M. C. Liu et al.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33883548" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A comprehensive characterization of the cell-free transcriptome reveals tissue- and subtype-specific biomarkers for cancer detection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27161973" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24419411" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29504847" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29504847" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29151359" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22215748" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : ROS1 rearrangements define a unique molecular class of lung cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22661537" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23070242" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23070242" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23070242" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23070242" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33591844" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33591844" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33646820" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31838015" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38197815" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29981925" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25264305" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Crizotinib in ROS1-rearranged non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30980071" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29596029" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25470694" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : First-line crizotinib versus chemotherapy in ALK-positive lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31669155" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26673800" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25351743" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27370605" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28520527" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Safety and preliminary clinical activity of ropotrectinib (TPX-0005), a ROS1/TRK/LK inhibitor, in advanced ROS1 fusion-positive NSCLC</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31399568" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21430269" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18093943" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19255323" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19117057" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19381876" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19037978" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19096300" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21248300" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17463250" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20129249" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26729443" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25971938" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26215952" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25971939" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24101053" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24101053" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24101053" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32877583" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32240796" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32469185" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31932802" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33676017" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Crizotinib in Patients With MET-Amplified NSCLC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8957065" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17459054" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22327623" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : RET, ROS1 and ALK fusions in lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22327624" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : KIF5B-RET fusions in lung adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23150706" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25436805" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25436805" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25436805" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37870973" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32846060" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36122315" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34118197" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35973665" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27825636" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23584301" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : A patient with lung adenocarcinoma and RET fusion treated with vandetanib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23533264" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25366691" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26944304" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28447912" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22071650" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21483012" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24297085" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25436800" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Clinical characteristics and course of 63 patients with BRAF mutant lung cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25273224" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26343582" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28783719" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30224342" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30224342" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30224342" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Dabrafenib in patients with BRAF V600-mutant advanced non-small cell lung cancer (NSCLC): A multicenter, open-label, phase II trial (BRF113928)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26287849" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34455067" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37270692" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37270692" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37270692" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30624546" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29466156" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32105622" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31838007" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38171156" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34077268" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32852072" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18623947" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Morphologic responses to a murine erythroblastosis virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : KRAS mutation and amplification status predicts sensitivity to antifolate therapies in non-small cell lung cancer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21782507" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23630215" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15597105" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19029981" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19029981" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36764316" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37098232" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37098232" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35658005" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37611121" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28492898" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34161704" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Acquired Resistance to KRASG12C Inhibition in Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22761469" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23610105" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28743157" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28743157" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34534430" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37694347" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29989854" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers: Results from a phase II basket trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16775247" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22325357" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35073148" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26598547" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : A phase II trial of poziotinib in EFR and HER2 exon 20 mutant non-small cell lung cancer (NSCLC)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 in NSCLC</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30596880" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32614698" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34843401" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34550757" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14679114" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15013588" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Trastuzumab deruxtecan in HER2-overexpressing metastatic non-small cell lung cancer: Interim results of DESTINY-Lung01</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33939491" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
